Ihe na-eme ka ihe na-egbuke egbuke

Lucinatant nke aha azumahia bu Surfacing bu medication di mmiri mmiri nke eji agwo umuaka nwere nsogbu n'iku ụme. Ọ bụ ihe na-eme ka mmadụ na-arụ ọrụ n'akpa ume maka ụmụ ọhụrụ na-enweghị ihe na-emepụta ihe zuru oke n'akpa nwa ha. Ọ bụ ezie na ọgwụ ndị mbụ nke klas ahụ, dị ka beractant (Survanta & Beraksurf), Calfactant (Infasurf) , na poractant (Curosurf), sitere na ụmụ anụmanụ, lucinactant bụ ihe aka mere. U.S. Food and Drug Administration (FDA) kwadoro ya maka iji ya na United States na Machị 6, 2012. 

 Ojiji ọgwụ 
A na-egosi Lucinactant iji melite ọrụ akpa ume ma belata oge na ihe ize ndụ nke ikuku ikuku n'ime ụmụaka. Enwere ike iji ya ruo afọ abụọ ma kọwaa ya maka ụmụaka a chọpụtara na ha nwere nsogbu iku ume siri ike na-esote nje dịka RSV ma ọ bụ influenza, gụnyere H1N1.   A na-ejikwa Lucinactant agwọ ọrịa meconium aspiration syndrome.[3]

 Akụkọ ihe mere eme 
E debere ntọala sayensị maka lucinactant na ụlọ nyocha nke Charles Cochrane na Scripps Research Institute na 1990s. Ọ bụ Discovery Laboratories nke Warrington, PA mepụtara ọgwụ ahụ. Ụzọ site na usoro nkwenye ahụ dị ogologo n'ụzọ a na-adịghị ahụkebe, na-egosipụta n'akụkụ ụfọdụ ihe ịma aka na usoro mmepụta nke dị mkpa ka a dozie tupu e nye nkwenye.